Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -658,963 | -327,845 | -1,115,463 | -1,054,601 | -669,705 |
| Depreciation Amortization | 11,426 | 5,839 | 18,857 | 12,904 | 7,753 |
| Accounts payable and accrued liabilities | 10,142 | 11,940 | 4,359 | 13,970 | 6,774 |
| Other Working Capital | -18,115 | -35,242 | 6,345 | -14,837 | -18,035 |
| Other Operating Activity | 209,151 | 95,376 | 242,509 | 378,259 | 231,501 |
| Operating Cash Flow | $-446,359 | $-249,932 | $-843,393 | $-664,305 | $-441,712 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -678 | -403 | -12,690 | -11,068 | -10,560 |
| Net Acquisitions | -36,179 | N/A | -6,706 | -6,706 | N/A |
| Sale Of Investment | N/A | N/A | 114,561 | N/A | N/A |
| Other Investing Activity | 511 | 508 | -139,434 | -140,048 | -143,751 |
| Investing Cash Flow | $-36,346 | $105 | $-44,269 | $-157,822 | $-154,311 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 159,899 | 159,899 | 159,899 |
| Debt Repayment | -14,471 | -7,344 | -29,452 | -22,108 | -14,685 |
| Common Stock Issued | 242,556 | 21,028 | 382,838 | 163,031 | N/A |
| Common Stock Repurchased | -41 | N/A | N/A | N/A | N/A |
| Dividend Paid | -6,000 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -6,695 | -6,207 | -13,823 | -11,692 | -10,579 |
| Financing Cash Flow | $215,349 | $7,477 | $499,462 | $289,130 | $134,635 |
| Exchange Rate Effect | -1,571 | -117 | 6,281 | N/A | N/A |
| Beginning Cash Position | 1,692,115 | 1,692,115 | 2,074,034 | 2,074,034 | 2,074,034 |
| End Cash Position | 1,423,188 | 1,449,648 | 1,692,115 | 1,541,037 | 1,612,646 |
| Net Cash Flow | $-268,927 | $-242,467 | $-381,919 | $-532,997 | $-461,388 |
| Free Cash Flow | |||||
| Operating Cash Flow | -446,359 | -249,932 | -843,393 | -664,305 | -441,712 |
| Capital Expenditure | -678 | -403 | -12,690 | -11,068 | -10,560 |
| Free Cash Flow | -447,037 | -250,335 | -856,083 | -675,373 | -452,272 |